eligibility_summary
Eligible: 18–75 with confirmed PDAC, locally advanced, unresectable or surgery‑declined, primary tumor <5 cm, ECOG 0–1, no prior upper‑abdominal RT or systemic therapy, adequate organ function, LVEF ≥50%, uses contraception, life expectancy ≥3 mo, consent. Exclude: GI invasion, pregnancy/breastfeeding, other cancer ≤5 yrs, serious CNS/psychiatric or cardiac disease/recent MI, need immunosuppression, active infection/TB/ILD, immunodeficiency (incl HIV/transplant), allergy, recent immunomodulators/herbals or other trials, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study in locally advanced pancreatic ductal adenocarcinoma testing: (1) SBRT (35–40 Gy in 5 fractions): ablative radiation causing DNA double-strand breaks and immunogenic cell death, can synergize with EGFR inhibition. (2) Nimotuzumab: humanized IgG1 anti-EGFR monoclonal antibody (h-R3) that blocks ligand binding to EGFR (HER1), suppressing RAS/RAF/MEK/ERK and PI3K/AKT signaling, inhibiting proliferation/survival, enhancing radiosensitivity, and mediating ADCC via NK cell Fcγ receptors. (3) Mono-chemotherapy: gemcitabine (nucleoside antimetabolite, DNA incorporation and ribonucleotide reductase inhibition) or S-1/capecitabine (oral 5-FU prodrugs, thymidylate synthase inhibition, RNA/DNA effects). Targets/pathways: EGFR-overexpressing pancreatic tumor cells, EGFR signaling, DNA replication/repair, thymidylate synthase, NK cell-mediated cytotoxicity.